{"id":47159,"date":"2022-08-10T18:02:06","date_gmt":"2022-08-10T16:02:06","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/maat-pharma-announces-update-on-u-s-fda-investigational-new-drug-application-for-maat013-in-patients-with-acute-graft-versus-host-disease\/"},"modified":"2022-08-10T18:02:06","modified_gmt":"2022-08-10T16:02:06","slug":"maat-pharma-announces-update-on-u-s-fda-investigational-new-drug-application-for-maat013-in-patients-with-acute-graft-versus-host-disease","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/maat-pharma-announces-update-on-u-s-fda-investigational-new-drug-application-for-maat013-in-patients-with-acute-graft-versus-host-disease\/","title":{"rendered":"MaaT Pharma Announces Update on U.S. FDA Investigational New Drug Application for MaaT013 in Patients with Acute Graft-versus-Host Disease"},"content":{"rendered":"
\n

LYON, France–(BUSINESS WIRE)–$MAAT<\/a>—MaaT Pharma<\/a><\/b><\/span> (EURONEXT: MAAT \u2013 the \u201cCompany\u201d), a French clinical-stage biotech and a pioneer in the development of Microbiome Ecosystem TherapiesTM<\/sup> (MET) dedicated to improving survival outcomes for patients with cancer<\/b>, today announced that it received a communication from the U.S. Food and Drug Administration (\u201cFDA\u201d or \u201cthe Agency\u201d) related to the Company\u2019s Investigational New Drug (IND) application filed in June 2021 to initiate in the U.S. an open-label, single-arm Phase 3 clinical trial of the Company\u2019s drug candidate, MaaT013, in patients with steroid-resistant acute Graft-versus-Host Disease (aGvHD). Following questions raised by the FDA in August 2021 on this application in a clinical hold letter, the Company had previously submitted a request for a Type A meeting, as well as detailed responses to the Agency\u2019s questions.\n<\/p>\n

<\/a><\/p>\n

\nA response letter was received in the evening on August 8th<\/sup>, 2022, Central European Time (CET). It indicates that the Agency maintains the clinical hold on MaaT013 in the U.S. and details the FDA\u2019s position on the clinical trial. The Agency acknowledged that it received satisfactory answers from the Company on multiple clinical and manufacturing-related questions that the Agency had initially raised. However, the Agency requires additional information, notably regarding the safety and efficacy of the Company\u2019s \u201cpooling\u201d approach (i.e.<\/i> mixing donations from multiple donors to achieve higher richness, diversity and better standardization of the product). The Company is also evaluating additional recommendations made by the Agency regarding the trial design.\n<\/p>\n

\n\u201cWe value the FDA\u2019s continued engagement as we seek to extend the Phase 3 clinical trial of MaaT013 to the U.S. <\/i>and we intend to work with the Agency to resolve the issues raised in the communication, while implementing a defined strategic plan to continue to deliver on our key milestones,\u201d<\/i> said <\/i>Herv\u00e9 Affagard, CEO and co-founder of MaaT Pharma<\/b>. \u201cTo date, data gathered from more than 120 patients with aGvHD who received MaaT013 in Europe as part of our early access program in France and our completed Phase 2 trial in Europe, indicated a positive safety and efficacy profile for MaaT013. We remain focused on bringing innovative and safe microbiome therapies to patients with refractory aGvHD.\u201d<\/i>\n<\/p>\n

\nMaaT Pharma is now in the process of preparing the next steps in the interaction with the FDA, potentially including a Type A meeting dedicated to discussing the remaining questions. In parallel and in line with its goal to reach patients globally, the Company will continue the development of MaaT013 in Europe and expand European recruitment for its ongoing Phase 3 trial<\/a> evaluating MaaT013 in 75 patients. There are currently 19 active clinical sites in France, Germany, and Spain and the Company has submitted clinical trial applications in three additional European countries. The overall expected timelines for the Phase 3 trial and, if approved, commercialization of MaaT013 in Europe remain unchanged.\n<\/p>\n

\nIn parallel, the Company continues to prepare for the initiation of a Phase 2\/3 trial in Europe to evaluate its second native (donor-derived) asset, MaaT033, in patients with blood cancers receiving allogeneic hematopoietic stem cell transplantation (allo-HSCT). This clinical study is expected to start in Q4 2022.\n<\/p>\n

\nThe Company also continues to prepare a first-in-human trial of its first co-fermented MaaT03X candidate in both Europe and the U.S. This new class of drug candidates aims to improve the anti-cancer efficacy of immune checkpoint inhibitors in patients with a yet undisclosed solid tumor having a high unmet need.\n<\/p>\n

\nAbout MaaT Pharma<\/b>\n<\/p>\n

\nMaaT Pharma, a clinical stage biotechnology company, has established a complete approach to restoring patient-microbiome symbiosis in oncology. Committed to treating cancer and graft-versus-host disease (GvHD), a serious complication of allogeneic stem cell transplantation, MaaT Pharma has launched, in March 2022 in Europe, a Phase 3 clinical trial for patients with acute GvHD, following the achievement of its proof of concept in a Phase 2 trial. Its powerful discovery and analysis platform, gutPrint\u00ae, supports the development and expansion of its pipeline by determining novel disease targets, evaluating drug candidates, and identifying biomarkers for microbiome-related conditions. The company\u2019s Microbiome Ecosystem Therapies are produced through a standardized cGMP manufacturing and quality control process to safely deliver the full diversity of the microbiome, in liquid and oral formulations. MaaT Pharma benefits from the commitment of world-leading scientists and established relationships with regulators to support the integration of the use of microbiome therapies in clinical practice.\n<\/p>\n

\nMaaT Pharma is the first company developing microbiome-based therapies listed on Euronext Paris (ticker: MAAT).\n<\/p>\n

\nForward-looking Statements<\/b>\n<\/p>\n

\nAll statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the Company\u2019s control. These statements may include, without limitation, any statements preceded by, followed by or including words such as \u201ctarget,\u201d \u201cbelieve,\u201d \u201cexpect,\u201d \u201caim,\u201d \u201cintend,\u201d \u201cmay,\u201d \u201canticipate,\u201d \u201cestimate,\u201d \u201cplan,\u201d \u201cproject,\u201d \u201cwill,\u201d \u201ccan have,\u201d \u201clikely,\u201d \u201cshould,\u201d \u201cwould,\u201d \u201ccould\u201d and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company\u2019s control that could cause the Company\u2019s actual results or performance to be materially different from the expected results or performance expressed or implied by such forward-looking statements.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nMaaT Pharma \u2013 Investor Relations<\/b>
Herv\u00e9 AFFAGARD
\n
Co-Founder and CEO
\n
Si\u00e2n Crouzet, COO\/ CFO
\n
+33 4 28 29 14 00
\n
invest@maat-pharma.com<\/a>\n<\/p>\n

\nMaaT Pharma \u2013 Media Relations<\/b>
Pauline RICHAUD
\n
Senior PR & Corporate Communications Manager
\n
+33 6 07 55 25 36
\n
prichaud@maat-pharma.com<\/a>\n<\/p>\n

\nTrophic Communications \u2013 Corporate and Medical Communications<\/b>
Jacob VERGHESE or
\n
Gretchen SCHWEITZER
\n
+49 89 2070 89831
\n
maat@trophic.eu<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

LYON, France–(BUSINESS WIRE)–$MAAT—MaaT Pharma (EURONEXT: MAAT \u2013 the \u201cCompany\u201d), a French clinical-stage biotech and a pioneer in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to improving survival outcomes for patients with cancer, today announced that it received a communication from the U.S. Food and Drug Administration (\u201cFDA\u201d or \u201cthe Agency\u201d) related to the Company\u2019s … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-47159","6":"format-standard","7":"category-industry"},"yoast_head":"\nMaaT Pharma Announces Update on U.S. FDA Investigational New Drug Application for MaaT013 in Patients with Acute Graft-versus-Host Disease - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/maat-pharma-announces-update-on-u-s-fda-investigational-new-drug-application-for-maat013-in-patients-with-acute-graft-versus-host-disease\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MaaT Pharma Announces Update on U.S. FDA Investigational New Drug Application for MaaT013 in Patients with Acute Graft-versus-Host Disease - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"LYON, France–(BUSINESS WIRE)–$MAAT—MaaT Pharma (EURONEXT: MAAT \u2013 the \u201cCompany\u201d), a French clinical-stage biotech and a pioneer in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to improving survival outcomes for patients with cancer, today announced that it received a communication from the U.S. Food and Drug Administration (\u201cFDA\u201d or \u201cthe Agency\u201d) related to the Company\u2019s ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/maat-pharma-announces-update-on-u-s-fda-investigational-new-drug-application-for-maat013-in-patients-with-acute-graft-versus-host-disease\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-08-10T16:02:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220810005587\/en\/729326\/21\/Nov_2018_new_version_MaaT_Pharma_logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/maat-pharma-announces-update-on-u-s-fda-investigational-new-drug-application-for-maat013-in-patients-with-acute-graft-versus-host-disease\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/maat-pharma-announces-update-on-u-s-fda-investigational-new-drug-application-for-maat013-in-patients-with-acute-graft-versus-host-disease\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"MaaT Pharma Announces Update on U.S. FDA Investigational New Drug Application for MaaT013 in Patients with Acute Graft-versus-Host Disease\",\"datePublished\":\"2022-08-10T16:02:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/maat-pharma-announces-update-on-u-s-fda-investigational-new-drug-application-for-maat013-in-patients-with-acute-graft-versus-host-disease\\\/\"},\"wordCount\":922,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/maat-pharma-announces-update-on-u-s-fda-investigational-new-drug-application-for-maat013-in-patients-with-acute-graft-versus-host-disease\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220810005587\\\/en\\\/729326\\\/21\\\/Nov_2018_new_version_MaaT_Pharma_logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/maat-pharma-announces-update-on-u-s-fda-investigational-new-drug-application-for-maat013-in-patients-with-acute-graft-versus-host-disease\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/maat-pharma-announces-update-on-u-s-fda-investigational-new-drug-application-for-maat013-in-patients-with-acute-graft-versus-host-disease\\\/\",\"name\":\"MaaT Pharma Announces Update on U.S. FDA Investigational New Drug Application for MaaT013 in Patients with Acute Graft-versus-Host Disease - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/maat-pharma-announces-update-on-u-s-fda-investigational-new-drug-application-for-maat013-in-patients-with-acute-graft-versus-host-disease\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/maat-pharma-announces-update-on-u-s-fda-investigational-new-drug-application-for-maat013-in-patients-with-acute-graft-versus-host-disease\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220810005587\\\/en\\\/729326\\\/21\\\/Nov_2018_new_version_MaaT_Pharma_logo.jpg\",\"datePublished\":\"2022-08-10T16:02:06+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/maat-pharma-announces-update-on-u-s-fda-investigational-new-drug-application-for-maat013-in-patients-with-acute-graft-versus-host-disease\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/maat-pharma-announces-update-on-u-s-fda-investigational-new-drug-application-for-maat013-in-patients-with-acute-graft-versus-host-disease\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/maat-pharma-announces-update-on-u-s-fda-investigational-new-drug-application-for-maat013-in-patients-with-acute-graft-versus-host-disease\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220810005587\\\/en\\\/729326\\\/21\\\/Nov_2018_new_version_MaaT_Pharma_logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220810005587\\\/en\\\/729326\\\/21\\\/Nov_2018_new_version_MaaT_Pharma_logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/maat-pharma-announces-update-on-u-s-fda-investigational-new-drug-application-for-maat013-in-patients-with-acute-graft-versus-host-disease\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MaaT Pharma Announces Update on U.S. FDA Investigational New Drug Application for MaaT013 in Patients with Acute Graft-versus-Host Disease\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"MaaT Pharma Announces Update on U.S. FDA Investigational New Drug Application for MaaT013 in Patients with Acute Graft-versus-Host Disease - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/maat-pharma-announces-update-on-u-s-fda-investigational-new-drug-application-for-maat013-in-patients-with-acute-graft-versus-host-disease\/","og_locale":"en_US","og_type":"article","og_title":"MaaT Pharma Announces Update on U.S. FDA Investigational New Drug Application for MaaT013 in Patients with Acute Graft-versus-Host Disease - Pharma Trend","og_description":"LYON, France–(BUSINESS WIRE)–$MAAT—MaaT Pharma (EURONEXT: MAAT \u2013 the \u201cCompany\u201d), a French clinical-stage biotech and a pioneer in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to improving survival outcomes for patients with cancer, today announced that it received a communication from the U.S. Food and Drug Administration (\u201cFDA\u201d or \u201cthe Agency\u201d) related to the Company\u2019s ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/maat-pharma-announces-update-on-u-s-fda-investigational-new-drug-application-for-maat013-in-patients-with-acute-graft-versus-host-disease\/","og_site_name":"Pharma Trend","article_published_time":"2022-08-10T16:02:06+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220810005587\/en\/729326\/21\/Nov_2018_new_version_MaaT_Pharma_logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/maat-pharma-announces-update-on-u-s-fda-investigational-new-drug-application-for-maat013-in-patients-with-acute-graft-versus-host-disease\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/maat-pharma-announces-update-on-u-s-fda-investigational-new-drug-application-for-maat013-in-patients-with-acute-graft-versus-host-disease\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"MaaT Pharma Announces Update on U.S. FDA Investigational New Drug Application for MaaT013 in Patients with Acute Graft-versus-Host Disease","datePublished":"2022-08-10T16:02:06+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/maat-pharma-announces-update-on-u-s-fda-investigational-new-drug-application-for-maat013-in-patients-with-acute-graft-versus-host-disease\/"},"wordCount":922,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/maat-pharma-announces-update-on-u-s-fda-investigational-new-drug-application-for-maat013-in-patients-with-acute-graft-versus-host-disease\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220810005587\/en\/729326\/21\/Nov_2018_new_version_MaaT_Pharma_logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/maat-pharma-announces-update-on-u-s-fda-investigational-new-drug-application-for-maat013-in-patients-with-acute-graft-versus-host-disease\/","url":"https:\/\/pharma-trend.com\/en\/maat-pharma-announces-update-on-u-s-fda-investigational-new-drug-application-for-maat013-in-patients-with-acute-graft-versus-host-disease\/","name":"MaaT Pharma Announces Update on U.S. FDA Investigational New Drug Application for MaaT013 in Patients with Acute Graft-versus-Host Disease - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/maat-pharma-announces-update-on-u-s-fda-investigational-new-drug-application-for-maat013-in-patients-with-acute-graft-versus-host-disease\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/maat-pharma-announces-update-on-u-s-fda-investigational-new-drug-application-for-maat013-in-patients-with-acute-graft-versus-host-disease\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220810005587\/en\/729326\/21\/Nov_2018_new_version_MaaT_Pharma_logo.jpg","datePublished":"2022-08-10T16:02:06+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/maat-pharma-announces-update-on-u-s-fda-investigational-new-drug-application-for-maat013-in-patients-with-acute-graft-versus-host-disease\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/maat-pharma-announces-update-on-u-s-fda-investigational-new-drug-application-for-maat013-in-patients-with-acute-graft-versus-host-disease\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/maat-pharma-announces-update-on-u-s-fda-investigational-new-drug-application-for-maat013-in-patients-with-acute-graft-versus-host-disease\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220810005587\/en\/729326\/21\/Nov_2018_new_version_MaaT_Pharma_logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220810005587\/en\/729326\/21\/Nov_2018_new_version_MaaT_Pharma_logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/maat-pharma-announces-update-on-u-s-fda-investigational-new-drug-application-for-maat013-in-patients-with-acute-graft-versus-host-disease\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"MaaT Pharma Announces Update on U.S. FDA Investigational New Drug Application for MaaT013 in Patients with Acute Graft-versus-Host Disease"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/47159","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=47159"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/47159\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=47159"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=47159"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=47159"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}